Table 1.
Characteristics of the included studies.
| Study | Disease | Country | Sample | Sample |
Age (years) |
Gender(male-female) |
Intervention |
Fecal type | FMT infusion pathway | Infusion volume | Outcomes | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | C | T | C | T | C | T | C | ||||||||
| Hvas 2019 (1) (20) | rCDI | Denmark | 48 | 24 | 24 | 22–90 | 24–87 | 4–20 | 11–13 | B | F | B | Nasal intestinal tube or colonoscopy | 50 g | ① |
| Hvas2019(2) (20) | rCDI | Denmark | 40 | 24 | 16 | 22–90 | 21–92 | 4–20 | 5–11 | B | E | B | Nasal intestinal tube or colonoscopy | 50 g | ① |
| Kelly 2016 (21) | rCDI | France, America | 46 | 22 | 24 | 48 ± 16 | 55 ± 14 | 4–18 | 5–19 | B | D | B,D | Colonoscopy | 100 g | ① |
| Lee 2016 (22) | rCDI | Canada | 219 | 111 | 108 | 72.5 ± 16.2 | 73.0 ± 16.4 | 37–74 | 36–72 | A | B | A,B | Enema | 64 g | ① |
| kao 2017 (23) | rCDI | Canada | 105 | 52 | 53 | 57.4 ± 19.1 | 58.7 ± 18.5 | 39%–61% | 24.6%–75.4% | B | C | B,C | Colonoscopy, oral | 360 ml, 40capsules | ① |
| Jiang 2017 (1) (24) | rCDI | America | 49 | 25 | 24 | 19–97 | 33–88 | 4–21 | 6–18 | A | B | A,B | Colonoscopy | 50 g | ① |
| Jiang 2017 (2) (24) | rCDI | America | 48 | 25 | 23 | 19–97 | 20–87 | 4–21 | 10–13 | A | C | A,C | Colonoscopy | 50 g | ① |
| Jiang 2017 (3) (24) | rCDI | America | 47 | 24 | 23 | 33–88 | 20–87 | 6–18 | 10–13 | B | C | B,C | Colonoscopy | 50 g | ① |
| Jiang 2018 (25) | rCDI | America | 65 | 34 | 31 | 63 | 67 | 9–25 | 10–21 | B | C | B,C | Enema, oral | 100–200 g/100 g | ① |
| Hota 2017 (26) | rCDI | Canada | 28 | 16 | 12 | 75.7 ± 14.5 | 69.6 ± 14.2 | 5–11 | 4–8 | A | E | A | Enema | 50 g | ① |
| Cammarota 2015 (27) | rCDI | Roman | 39 | 20 | 19 | 71 ± 15 | 75 ± 11 | 8–12 | 8–11 | A | E | A | Colonoscopy | 152 ± 32 g | ① |
| van Nood 2013 (28) | rCDI | Netherlands | 29 | 16 | 13 | 73 ± 13 | 66 ± 14 | 8–8 | 5–7 | A | E | A | Nasal-duodenum tube | 141 ± 71 g | ① |
| Rode AA 2021(1)(29) | rCDI | Denmark | 65 | 34 | 31 | 75(66–81) | 76(65–84) | 14–20 | 17–14 | B | E | B | Enema | 50 g | ① |
| Rode AA 2021 (2) (29) | rCDI | Denmark | 67 | 34 | 33 | 75(66–81 | 67(60–79) | 14–20 | 14–19 | B | G | B | Enema | 50 g | ① |
RCDI, Recurrent clostridium difficile infection; T, Treatment group; C, Control group; ① Cure rate.
(A) fresh fecal bacteria; (B) frozen fecal bacteria; (C) lyophilized fecal bacteria; (D) autologous fecal bacteria; (E) vancomycin; (F) fidaxomicin; (G) rectal bacteriotherapy.